임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 16-03-13 23:07
논문번호 79
논문제목(영문) Clinical outcomes and optimal treatment for stent fracture after drug-eluting stent implantation.
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 공저자
주저자명 Lee SE
교신저자명 Jeong MH
공동저자명 Lee SE, Jeong MH, Kim IS, Ko JS, Lee MG, Kang WY, Kim SH, Sim DS, Park KH, Yoon NS, Yoon HJ, Kim KH, Hong YJ, Park HW, Kim JH, Ahn YK, Cho JG, Park JC, Kang JC;
게제년월일 2009-02-12
ISSN 0914-5087
Impact Factor 2.782
학술지명 Journal of cardiology
서지사항 0집 / 53권 / 3호,   페이지(422 - 428)
요약초록문
(Abstract) 입력		 BACKGROUND:
Many studies have suggested that in the era of drug-eluting stents (DES) one of the causes of in-stent restenosis is stent fracture (SF). Yet there have been few studies of the major adverse cardiac events and treatment of DES SF.
METHODS AND RESULTS:
From September 2003 to May 2008, 3365 patients received successful stent implantation with DES, of whom 1009 patients underwent a follow-up coronary angiography irrespective of symptoms. Seventeen SFs were detected in 15/1009 patients (1.5%). All SF patients were continued on medication with combination antiplatelet therapy, regardless of angina symptoms. If in-stent restenosis at the fractured site was significant, we performed coronary interventions even in patients without ischemic symptoms. Patients were treated with heterogenous DES for restenosis lesions (5/8 patients), and the rest were treated with either homogenous DES (2 patients), or plain old balloon angioplasty (1 patient) or medical treatment (7 patients). None of the SF patients suffered from cardiac death during a follow-up period of 20.4+/-12.3 months.
CONCLUSION:
If patients with SF were continued on combination antiplatelet therapy irrespective of ischemic symptoms, there would occur a low rate of major adverse cardiac events, especially cardiac death associated with SF.
파일  c79.+J+Cardiol.+2009;53(3)422-428..pdf (696.8K) DATE : 2021-05-25 11:16:32